Health ❯ Healthcare

Cancer Research

Clinical Trials Immunotherapy Biomarkers Tumor Microenvironment Clinical Studies Tumor Biology Epidemiology Therapeutics Breast Cancer Innovative Therapies

ECOG-ACRIN Review Finds Black AML Patients Have Worse Survival Independent of Cytogenetics

Researchers call for integrated datasets to pinpoint the drivers of the survival gap.

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show

American Cancer Society Endorses Self-Collected HPV Swabs for Cervical Cancer Screening

AACR Releases First Pediatric Cancer Progress Report, Citing Record Survival and Persistent Gaps

MD Anderson Launches $2.5 Billion Campaign to Accelerate Cancer Research and Care

Global Trial Finds Many Post-Mastectomy Patients Can Skip Chest-Wall Radiotherapy

Two Nature Studies Show FSP1 Blockade Triggers Ferroptosis and Shrinks Tumors in Mice

Mexico Moves to Tackle Breast Cancer With New Bills and Major Screening Investment

Targeted Nanoparticles Help Checkpoint Drugs Erase Ovarian Tumors in Mice

UK Launches National Trial of Breath Test to Spot Pancreatic Cancer Early

Inhibrx Drug Extends PFS in Chondrosarcoma Phase 2 as Shares Jump Over 70%

mRNA Covid Vaccination Linked to Longer Survival When Given Near Cancer Immunotherapy, Nature Study Finds

Small Pediatric Study Links Pazopanib to Improved Two-Year Survival in Metastatic Ewing Sarcoma

NHS Delivers First Histotripsy Treatment in Europe at Addenbrooke’s

mRNA COVID Vaccination Linked to Longer Survival With Cancer Immunotherapy, Data Presented at ESMO

Galleri Multi-Cancer Blood Test Posts 61.6% PPV and 99.6% Specificity in Pathfinder 2

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer

Galleri Blood Test Confirms Cancer in 62% of Positive Screens in Major Trial